{"id":508679,"date":"2021-07-01T07:03:18","date_gmt":"2021-07-01T11:03:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\/"},"modified":"2021-07-01T07:03:18","modified_gmt":"2021-07-01T11:03:18","slug":"leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\/","title":{"rendered":"Leading Independent Proxy Advisory Firm Glass Lewis &amp; Co. Recommends Baudax Bio Shareholders Vote \u201cFor\u201d the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MALVERN, Pa., July  01, 2021  (GLOBE NEWSWIRE) &#8212; Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that Glass Lewis &amp; Co., a leading proxy advisory firm, has recommended that Baudax Bio shareholders vote \u201cFOR\u201d Item 1 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on June 14, 2021 in connection with its Special Meeting, which seeks to amend Baudax Bio\u2019s Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock from 100 million shares to 190 million shares. The Special Meeting will be held on July 13, 2021 at 9:00 a.m. ET and will be held virtually at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ENFw6PFK2W5ACAdNA0earsmMOSwVhMt9GMbg9LHn8hVCOTPUpwgrsjHe3XOdzFoWXMw0eoLapbzl8bprF-nXCL-4gLmGLDxLPqxQHaqCCl-eqyzdYeJ9BloydB4TrBIF4DSPCPkq3ehrgpbnWgMDOYefYXtaZDd3bLkM44f6_e4=\" rel=\"nofollow noopener\" target=\"_blank\">www.virtualshareholdermeeting.com\/BXRX2021<\/a>.<\/p>\n<p align=\"justify\">Glass Lewis is widely recognized as one of the leading independent proxy voting and corporate governance advisory firms, and its recommendations are relied upon by thousands of major institutional investment firms, mutual funds and other fiduciaries throughout the United States.<\/p>\n<p align=\"justify\">\u201cThe support from Glass Lewis, combined with the positive recommendation from Institutional Shareholder Services, to vote in favor of the additional authorized shares conveys alignment across two leading independent advisory firms,\u201d said Gerri Henwood, President and CEO of Baudax Bio. \u201cWe feel that through these recommendations both independent advisory firms recognize the importance of increasing the number of authorized shares and what it means for the Company\u2019s ability achieve its goals and diversify its shareholder base.\u201d<\/p>\n<p align=\"justify\">Glass Lewis &amp; Co. and Institutional Shareholder Services Inc. are independent proxy advisory firms and do not have any business relationship with Baudax Bio. Baudax Bio did not engage or compensate either firm for its analysis or recommendations.<\/p>\n<p align=\"justify\">Baudax shareholders are urged to vote as Glass Lewis &amp; Co. and Institutional Shareholder Services Inc. recommend by voting \u201cFOR\u201d the proposed increase in authorized shares and the adjournment of the Special Meeting of shareholders. Shareholders with questions may call Okapi Partners LLC at (855) 208-8902 or by email at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j4P96yOHg-GQkHzYL70VdW-mAXswlX41j91rSe1oX0tdrv2ekKxy32iL5GOjf-Z0yI9yaJxNn7S_MYB4Tb4Gk_AGeVMqwIjnsJXLf7DnddY=\" rel=\"nofollow noopener\" target=\"_blank\">info@okapipartners.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>All shareholders are encouraged to vote no matter how many shares you own. You are encouraged to submit your vote as soon as possible. Please submit your vote online at www.proxyvote.com or by telephone at 1-800-690-6903. Shareholders needing assistance voting or have questions may contact Baudax Bio\u2019s proxy solicitation firm, Okapi Partners, at info@okapipartners.com or (855) 208-8902.<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>About Baudax Bio<\/strong>\n      <\/p>\n<p align=\"justify\">Baudax Bio is a pharmaceutical company focused on developing and commercializing innovative products for acute care settings. The launch of Baudax Bio\u2019s first commercial product ANJESO<sup>\u00ae<\/sup>\u00a0began in mid-2020. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs which is currently in preclinical studies. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fXGQLg5jLsQdngYnQqyiFyP50FOn7CQCjDqp7LoZGIQ1lM4pXcEfEwAXYuIPNmnmV6FxPPqU0NObFImSGRgEPA==\" rel=\"nofollow noopener\" target=\"_blank\">www.baudaxbio.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward Looking Statements <\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Baudax Bio\u2019s expectations about its future performance and opportunities that involve substantial risks and uncertainties. When used herein, the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cmay,\u201d \u201cupcoming,\u201d \u201cplan,\u201d \u201ctarget,\u201d \u201cgoal,\u201d \u201cintend,\u201d and \u201cexpect,\u201d and similar expressions, as they relate to Baudax Bio or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information available to Baudax Bio as of the date of publication on this internet site and are subject to a number of risks, uncertainties, and other factors that could cause Baudax Bio\u2019s performance to differ materially from those expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, among other things, risks related to the ongoing economic and social consequences of the COVID-19 pandemic, including any adverse impact on the commercial launch of ANJESO\u00ae or disruption in supply chain, Baudax Bio\u2019s ability to maintain regulatory approval for ANJESO, Baudax Bio\u2019s ability to successfully commercialize ANJESO; the acceptance of ANJESO by the medical community, including physicians, patients, health care providers and hospital formularies; Baudax Bio\u2019s ability and that of Baudax Bio\u2019s third party manufacturers to successfully scale-up the commercial manufacturing process for ANJESO, Baudax Bio\u2019s ability to produce commercial supply in quantities and quality sufficient to satisfy market demand for ANJESO, Baudax Bio\u2019s ability to raise future financing for continued product development, payment of milestones and ANJESO commercialization, Baudax Bio\u2019s ability to pay its debt and satisfy conditions necessary to access future tranches of debt, Baudax Bio\u2019s ability to comply with the financial and other covenants under its credit facility, Baudax Bio\u2019s ability to manage costs and execute on its operational and budget plans, the accuracy of Baudax Bio\u2019s estimates of the potential market for ANJESO, Baudax Bio\u2019s ability to achieve its financial goals; and Baudax Bio\u2019s ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection. These forward-looking statements should be considered together with the risks and uncertainties that may affect Baudax Bio\u2019s business and future results included in Baudax Bio\u2019s filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are based on information currently available to Baudax Bio, and Baudax Bio assumes no obligation to update any forward-looking statements except as required by applicable law.<\/p>\n<p>\n        <strong>CONTACT:<\/strong>\n      <\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong>\n      <\/p>\n<p>Argot Partners<br \/>Sam Martin \/ Claudia Styslinger<br \/>(212) 600-1902<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=co478Lx2FT1uWME1dsuCgHR4zSeNj1Ubcu0T_S1b1fh0wwMuNr5-Qz-U5c8Qd9eiN2zVk1HJRUpHtfOGqaWDEaLqSUbKcS51AU_DfBndAoPtEiGqPmtlxFC__Vd1yhT4\" rel=\"nofollow noopener\" target=\"_blank\">baudaxbio@argotpartners.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong>\n      <\/p>\n<p>Argot Partners<br \/>David Rosen<br \/>(212) 600-1902<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=X6DOTZdzPsKHvKFQ6KW6lo5U2hKjAk3sMGjch063Wh-q5NWPy9LjqQppKw9DhnlJOyLxekG01dPThdg_Q_dHCcq7YG2BOJEAWWJ2_2mG-UiM71TH-jCkwCfMOv7N6Uzr\" rel=\"nofollow noopener\" target=\"_blank\">david.rosen@argotpartners.com<\/a><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzU4MSM0Mjc3OTgzIzIxOTM0NDI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/331aa6c0-3acc-4cfd-acab-86cc1ce391d6\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MALVERN, Pa., July 01, 2021 (GLOBE NEWSWIRE) &#8212; Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that Glass Lewis &amp; Co., a leading proxy advisory firm, has recommended that Baudax Bio shareholders vote \u201cFOR\u201d Item 1 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on June 14, 2021 in connection with its Special Meeting, which seeks to amend Baudax Bio\u2019s Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock from 100 million shares to 190 million shares. The Special Meeting will be held on July 13, 2021 at 9:00 a.m. ET and will be held &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Leading Independent Proxy Advisory Firm Glass Lewis &amp; Co. Recommends Baudax Bio Shareholders Vote \u201cFor\u201d the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-508679","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Leading Independent Proxy Advisory Firm Glass Lewis &amp; Co. Recommends Baudax Bio Shareholders Vote \u201cFor\u201d the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Leading Independent Proxy Advisory Firm Glass Lewis &amp; Co. Recommends Baudax Bio Shareholders Vote \u201cFor\u201d the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MALVERN, Pa., July 01, 2021 (GLOBE NEWSWIRE) &#8212; Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that Glass Lewis &amp; Co., a leading proxy advisory firm, has recommended that Baudax Bio shareholders vote \u201cFOR\u201d Item 1 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on June 14, 2021 in connection with its Special Meeting, which seeks to amend Baudax Bio\u2019s Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock from 100 million shares to 190 million shares. The Special Meeting will be held on July 13, 2021 at 9:00 a.m. ET and will be held &hellip; Continue reading &quot;Leading Independent Proxy Advisory Firm Glass Lewis &amp; Co. Recommends Baudax Bio Shareholders Vote \u201cFor\u201d the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-01T11:03:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzU4MSM0Mjc3OTgzIzIxOTM0NDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Leading Independent Proxy Advisory Firm Glass Lewis &amp; Co. Recommends Baudax Bio Shareholders Vote \u201cFor\u201d the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders\",\"datePublished\":\"2021-07-01T11:03:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\\\/\"},\"wordCount\":946,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MzU4MSM0Mjc3OTgzIzIxOTM0NDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\\\/\",\"name\":\"Leading Independent Proxy Advisory Firm Glass Lewis &amp; Co. Recommends Baudax Bio Shareholders Vote \u201cFor\u201d the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MzU4MSM0Mjc3OTgzIzIxOTM0NDI=\",\"datePublished\":\"2021-07-01T11:03:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MzU4MSM0Mjc3OTgzIzIxOTM0NDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MzU4MSM0Mjc3OTgzIzIxOTM0NDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leading Independent Proxy Advisory Firm Glass Lewis &amp; Co. Recommends Baudax Bio Shareholders Vote \u201cFor\u201d the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Leading Independent Proxy Advisory Firm Glass Lewis &amp; Co. Recommends Baudax Bio Shareholders Vote \u201cFor\u201d the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\/","og_locale":"en_US","og_type":"article","og_title":"Leading Independent Proxy Advisory Firm Glass Lewis &amp; Co. Recommends Baudax Bio Shareholders Vote \u201cFor\u201d the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders - Market Newsdesk","og_description":"MALVERN, Pa., July 01, 2021 (GLOBE NEWSWIRE) &#8212; Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that Glass Lewis &amp; Co., a leading proxy advisory firm, has recommended that Baudax Bio shareholders vote \u201cFOR\u201d Item 1 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on June 14, 2021 in connection with its Special Meeting, which seeks to amend Baudax Bio\u2019s Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock from 100 million shares to 190 million shares. The Special Meeting will be held on July 13, 2021 at 9:00 a.m. ET and will be held &hellip; Continue reading \"Leading Independent Proxy Advisory Firm Glass Lewis &amp; Co. Recommends Baudax Bio Shareholders Vote \u201cFor\u201d the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-01T11:03:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzU4MSM0Mjc3OTgzIzIxOTM0NDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Leading Independent Proxy Advisory Firm Glass Lewis &amp; Co. Recommends Baudax Bio Shareholders Vote \u201cFor\u201d the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders","datePublished":"2021-07-01T11:03:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\/"},"wordCount":946,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzU4MSM0Mjc3OTgzIzIxOTM0NDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\/","name":"Leading Independent Proxy Advisory Firm Glass Lewis &amp; Co. Recommends Baudax Bio Shareholders Vote \u201cFor\u201d the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzU4MSM0Mjc3OTgzIzIxOTM0NDI=","datePublished":"2021-07-01T11:03:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzU4MSM0Mjc3OTgzIzIxOTM0NDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzU4MSM0Mjc3OTgzIzIxOTM0NDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/leading-independent-proxy-advisory-firm-glass-lewis-co-recommends-baudax-bio-shareholders-vote-for-the-proposed-additional-authorized-shares-at-upcoming-special-meeting-of-sha\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Leading Independent Proxy Advisory Firm Glass Lewis &amp; Co. Recommends Baudax Bio Shareholders Vote \u201cFor\u201d the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/508679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=508679"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/508679\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=508679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=508679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=508679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}